ES2173204T3 - Formacion de particulas pequeñas. - Google Patents

Formacion de particulas pequeñas.

Info

Publication number
ES2173204T3
ES2173204T3 ES95938091T ES95938091T ES2173204T3 ES 2173204 T3 ES2173204 T3 ES 2173204T3 ES 95938091 T ES95938091 T ES 95938091T ES 95938091 T ES95938091 T ES 95938091T ES 2173204 T3 ES2173204 T3 ES 2173204T3
Authority
ES
Spain
Prior art keywords
training
small particles
organic compounds
amphifil
waterful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95938091T
Other languages
English (en)
Inventor
Sylvan Frank
Jan-Erik Lofroth
Levon Bostanian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Application granted granted Critical
Publication of ES2173204T3 publication Critical patent/ES2173204T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/10—Complex coacervation, i.e. interaction of oppositely charged particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Saccharide Compounds (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Surgical Instruments (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Confectionery (AREA)
  • Soft Magnetic Materials (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A LA FORMACION DE PEQUEÑAS PARTICULAS DE COMPUESTOS ORGANICOS MEDIANTE LA PRECIPITACION DE DICHOS COMPUESTOS ORGANICOS EN UN MEDIO ACUOSO QUE CONTIENE COMPLEJOS POLIMERO/AMFIFILO. EL PROCESO ES USADO PREFERIBLEMENTE PARA PREPARAR UN COMPUESTO ACTIVO FARMACEUTICAMENTE FACILMENTE SOLUBLE.
ES95938091T 1994-11-09 1995-11-03 Formacion de particulas pequeñas. Expired - Lifetime ES2173204T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9403846A SE9403846D0 (sv) 1994-11-09 1994-11-09 Small particle formation

Publications (1)

Publication Number Publication Date
ES2173204T3 true ES2173204T3 (es) 2002-10-16

Family

ID=20395907

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95938091T Expired - Lifetime ES2173204T3 (es) 1994-11-09 1995-11-03 Formacion de particulas pequeñas.

Country Status (27)

Country Link
US (1) US5780062A (es)
EP (1) EP0788350B1 (es)
JP (1) JP4098827B2 (es)
KR (1) KR970706799A (es)
CN (1) CN1165478A (es)
AT (1) ATE213625T1 (es)
AU (1) AU700644B2 (es)
BR (1) BR9509720A (es)
CA (1) CA2203512A1 (es)
CZ (1) CZ129597A3 (es)
DE (1) DE69525639T2 (es)
DK (1) DK0788350T3 (es)
EE (1) EE9700214A (es)
ES (1) ES2173204T3 (es)
FI (1) FI118511B (es)
HU (1) HUT77629A (es)
IL (1) IL115878A0 (es)
IS (1) IS4467A (es)
NO (1) NO971986D0 (es)
NZ (1) NZ295497A (es)
PL (1) PL320425A1 (es)
PT (1) PT788350E (es)
SE (1) SE9403846D0 (es)
SK (1) SK55997A3 (es)
TR (1) TR199501400A2 (es)
WO (1) WO1996014833A1 (es)
ZA (1) ZA959386B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US7029700B2 (en) * 2000-01-14 2006-04-18 Brown University Research Foundation Micronized freeze-dried particles
WO2001052818A1 (en) 2000-01-19 2001-07-26 Pharmaceutical Discovery Corporation Dry powder formulations of antihistamine for nasal administration
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
AU2002249836B2 (en) * 2000-12-22 2006-12-14 Baxter International Inc. Method for preparing submicron particle suspensions
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6623761B2 (en) 2000-12-22 2003-09-23 Hassan Emadeldin M. Method of making nanoparticles of substantially water insoluble materials
DE10117049A1 (de) * 2001-04-05 2002-10-17 Novartis Ag Zusammensetzung
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
EP1416917B1 (en) * 2001-08-06 2007-06-27 AstraZeneca AB Aqueous dispersion comprising stable nanoparticles of a water-insoluble active and an excipient like middle chain triglycerides (mct)
JP2004537401A (ja) * 2001-08-08 2004-12-16 ブラウン ユニバーシティ リサーチ ファウンデーション 疎水性薬物の微粉砕方法
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
US20040028747A1 (en) * 2002-08-06 2004-02-12 Tucker Christopher J. Crystalline drug particles prepared using a controlled precipitation process
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7511079B2 (en) * 2003-03-24 2009-03-31 Baxter International Inc. Methods and apparatuses for the comminution and stabilization of small particles
CN1791386A (zh) * 2003-05-19 2006-06-21 巴克斯特国际公司 抗癫痫和抗痴呆药物以及免疫抑制剂的小－颗粒药物制剂
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
JP2006527770A (ja) * 2003-06-18 2006-12-07 アストラゼネカ アクチボラグ Ｃｂ１モジュレーターとしての２−置換５，６−ジアリール−ピラジン誘導体
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2004112747A2 (en) * 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US8986736B2 (en) * 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
CA2539494C (en) 2003-09-22 2011-12-06 Baxter International Inc. High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
US20050181059A1 (en) * 2003-09-30 2005-08-18 Spherics, Inc. Nanoparticulate therapeutic biologically active agents
DE10351087A1 (de) * 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
RU2006130958A (ru) * 2004-01-29 2008-03-10 Бакстер Интернэшнл Инк. (Us) Наносуспензии антиретровирусных агентов для улучшенной доставки в центральную нервную систему
EP1711163A2 (en) * 2004-02-05 2006-10-18 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
CA2565972A1 (en) * 2004-06-15 2005-12-29 Baxter International Inc. Ex-vivo application of solid microparticulate therapeutic agents
US20080171687A1 (en) * 2004-09-16 2008-07-17 Abraxis Bioscience, Inc. Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
EP2152274A4 (en) * 2007-05-07 2010-07-21 Questor Pharmaceuticals Inc NASAL ADMINISTRATION OF BENZODIAZEPINES
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
US8101274B2 (en) * 2007-06-11 2012-01-24 Spedden Richard H Solid state membranes with surface-embedded glycosylated amphiphilic molecules and micelles formed therefrom
GB0714223D0 (en) * 2007-07-20 2007-08-29 Fujifilm Mfg Europe Bv Preparation of fine particles
EP2240162A4 (en) 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
EP2231169B1 (en) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
CN101965195A (zh) 2008-03-05 2011-02-02 巴克斯特国际公司 用于药物投送的组合物和方法
JP5613657B2 (ja) 2008-03-28 2014-10-29 ヘイル バイオファーマ ベンチャーズ，エルエルシー ベンゾジアゼピン組成物の投与
CN101278921B (zh) * 2008-06-03 2010-06-09 海南百那医药发展有限公司 盐酸托烷司琼微囊及其注射剂生产方法
US20100151037A1 (en) * 2008-08-07 2010-06-17 Yivan Jiang Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound
US8889168B2 (en) 2008-08-07 2014-11-18 Bioactive Surgical Inc. Stem cell capture and immobilization coatings for medical devices and implants
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
CN102784103A (zh) * 2011-05-16 2012-11-21 中国科学院上海药物研究所 一种通过混合胶束技术制备的普罗布考纳米混悬液及其制备方法
US20140199397A1 (en) * 2011-06-10 2014-07-17 Daniel Levin Benzoyl Peroxide Microparticle Process
DK3415139T3 (da) 2011-06-14 2022-06-20 Neurelis Inc Administration af benzodiazepin
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2016181406A1 (en) * 2015-05-08 2016-11-17 Davuluri Ramamohan Rao Improved process for the preparation of aripiprazole with reduced particle size
US12599611B2 (en) 2021-06-10 2026-04-14 Neurelis, Inc. Methods and compositions for treating seizure disorders in pediatric patients

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4606940A (en) * 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
JPH0249720A (ja) * 1988-05-18 1990-02-20 Mitsubishi Kasei Corp 難溶性薬剤組成物
SE464743B (sv) * 1989-06-21 1991-06-10 Ytkemiska Inst Foerfarande foer framstaellning av laekemedelspartiklar
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.

Also Published As

Publication number Publication date
BR9509720A (pt) 1997-10-21
HUT77629A (hu) 1998-06-29
SE9403846D0 (sv) 1994-11-09
US5780062A (en) 1998-07-14
EE9700214A (et) 1998-04-15
WO1996014833A1 (en) 1996-05-23
FI971947A0 (fi) 1997-05-07
NO971986L (no) 1997-04-29
EP0788350B1 (en) 2002-02-27
CZ129597A3 (en) 1997-12-17
DE69525639T2 (de) 2002-08-29
DK0788350T3 (da) 2002-04-29
IL115878A0 (en) 1996-01-31
ATE213625T1 (de) 2002-03-15
NO971986D0 (no) 1997-04-29
ZA959386B (en) 1996-05-09
DE69525639D1 (de) 2002-04-04
KR970706799A (ko) 1997-12-01
FI971947L (fi) 1997-05-07
TR199501400A2 (tr) 1996-06-21
AU700644B2 (en) 1999-01-14
CA2203512A1 (en) 1996-05-23
PT788350E (pt) 2002-07-31
PL320425A1 (en) 1997-09-29
JP4098827B2 (ja) 2008-06-11
JPH10508840A (ja) 1998-09-02
IS4467A (is) 1997-04-21
FI118511B (fi) 2007-12-14
SK55997A3 (en) 1998-01-14
NZ295497A (en) 1998-05-27
CN1165478A (zh) 1997-11-19
EP0788350A1 (en) 1997-08-13
AU3885195A (en) 1996-06-06

Similar Documents

Publication Publication Date Title
PT788350E (pt) Formacao de particulas pequenas
BR0210519A (pt) Composições farmacêuticas de adsorvatos de fármaco amorfo
BR9815464A (pt) Polìmero, processo de preparação de polìmeros, utilização de um polìmero, composição, associação de pelo menos um polìmero com pelo menos um composto e composição cosmética
DE60312333D1 (de) Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
SV1994000028A (es) Nuevas sulfonilamino pirimidinas, ref. 10916 sv.
PA8444201A1 (es) Derivados ciclicos de sulfona
DK0436217T3 (da) Antiinflammatorisk analgetisk plaster
MX9303124A (es) Compuestos organicos de benzodiazepina, procedimiento para su preparacion y formulaciones farmaceuticas que los contienen.
ES2178268T3 (es) Formulaciones de liberacion controlada.
ES2164088T3 (es) Antagonistas de la sustancia p para el tratamiento de la emesis.
FI902877A0 (fi) N-substituerade lauramider, deras framstaellning och sammansaettningar, daer de aer naervarande.
ATE264352T1 (de) Modifizierte polycyclische polymere
ES2192256T3 (es) Soluciones farmaceuticas inyectables que contienen paracetamol y combinaciones de paracetamol con otras sustancias activas.
AR024959A1 (es) Una composicion farmaceutica liquida basada en paracetamol
MX174635B (es) Composicion liquida suavizante
ATE464043T1 (de) Pharmazeutische zusammensetzung enthaltend l- arginin
BR0111915A (pt) 5-aminoalquilpirazolo[4,3-d]pirimidinas
ES2187184T3 (es) Fosfoepoxidos, procedimiento de fabricacion y aplicaciones.
ATE323602T1 (de) Bildaufzeichnungsmaterial und flachdruckplatte mit diesem bildaufzeichnungsmaterial
AR014325A1 (es) Uso de glicinas n,n'-disustituidos o derivados de los mismos como desinfectantes antituberculosos y los desinfectantes antituberculososformulados con dichas glicinas n,n'-disustituidos
DE69805860D1 (de) Wasserlösliche ähnliche verbindungen und medicament-vorstufe von paclitaxel
ES2176222T3 (es) Composiciones farmaceuticas que contienen hirudina.
ES2103220A1 (es) Desodorantes de los efluentes de papelera a base de ester de acido undecilenico.
AR002981A1 (es) Un envase que aloja una composicion farmaceutica que comprende una solucion acuosa de clorhidrato de procaterol, y una composicion farmaceutica quecomprende una solucion acuosa de clorhidrato de procaterol
PE20000262A1 (es) Composiciones para la prevencion y tratamiento del resfriado y sintomas similares a la gripe asociados con infecciones del sistema respiratorio y su metodo de uso

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 788350

Country of ref document: ES